Key result
Continuous IV epoprostenol remains first-choice therapy for severe PAH despite complex delivery systems.
Why the study?
Epoprostenol remains the first choice therapy for severe PAH patients despite its short half-life and complicated delivery system, necessitating a pharmacokinetic evaluation and comparison with other prostacyclin analogs.
What are the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of continuous intravenous epoprostenol compared to other prostacyclin analogs in patients with severe PAH?
What are the pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of continuous intravenous epoprostenol compared to other prostacyclin analogs in patients with severe PAH?
This review highlights that despite pharmacokinetic challenges like a short half-life, continuous intravenous epoprostenol remains the first-line therapy for severe PAH.
Sustains epoprostenol as initial therapy for severe PAH; leaves open comparative role versus modern combinations in prospective trials.
IMPORTANCE OF THE FIELD: prostacyclin is the main arachidonic acid metabolite and its decrease has been proven to be important in the pathophysiology of the pulmonary arterial hypertension (PAH). Epoprostenol has been the first analog of prostacyclin to be approved for the treatment of PAH and despite the development of therapeutic options, the last recommendations of European Societies of Cardiology and Pulmonology maintain it as the first choice therapy for severe patients in the WHO functional class IV. In this review, we focus on pharmacokinetics of epoprostenol characterized by its instability in aqueous biological fluids and compare its pharmacokinetics with other stable analogs of prostacyclin. Moreover, pharmacodynamics, clinical efficacy and safety of epoprostenol were studied. AREAS COVERED IN THIS REVIEW: a literature search and review of the studies published on epoprostenol were carried out using the MEDLINE database. WHAT THE READER WILL GAIN: the paper provides the reader with information on epoprostenol pharmacokinetics and comparison with other analogs of prostacyclin. This paper also provides data on pharmacodynamics, clinical efficacy, safety and tolerability of epoprostenol. TAKE HOME MESSAGE: despite epoprostenol's short half-life and complicated delivery system, this treatment remains the first choice therapy for severe PAH patients.
No takes yet. Share an insight, caveat, or question.
Chaumais et al. (2010) conducted a review in Pulmonary arterial hypertension (PAH). Epoprostenol vs. Other stable analogs of prostacyclin was evaluated. Continuous intravenous epoprostenol remains the first choice therapy for severe pulmonary arterial hypertension despite its short half-life and complicated delivery system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: